▎药明康德内容团队编辑Actuate Therapeutics今日公布其在研GSK-3β小分子抑制剂elraglusib联合吉西他滨/白蛋白紫杉醇（GnP），用于转移性胰腺导管腺癌（mPDAC）一线治疗2期试验Actuate-1801 Part ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding ...